Otenaproxesul

Otenaproxesul
Clinical data
Other namesATB-352[1]
Routes of
administration		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
  • 4-Carbamothioylphenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H19NO3S
Molar mass365.45 g·mol−1
3D model (JSmol)
  • COC1=CC2=CC=C(C=C2C=C1)C(C)C(=O)OC3=CC=C(C=C3)C(N)=S
  • InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26)/t13-/m0/s1
  • Key:YCNMAPLPQYQJFC-ZDUSSCGKSA-N

Otenaproxesul is a analgesic and anti-inflammatory drug being developed by Antibe Therapeutics. An NSAID structurally derived from naproxen, in 2016 it received approval to commence phase II clinical trials as a treatment for osteoarthritis after completing phase I clinical trials in 2015.[2] In 2018, the drug completed trials for gastrointestinal safety, and in 2020 completed phase IIb trials on efficacy of pain reduction.[3] Initial phase III clinical trials in 2021 failed to meet the necessary criteria to advance to the next phase.

Other in vivo studies have demonstrated a reduction in zymosan-induced pain and inflammation and cytokine-induced bone loss.[4] Preclinical studies have also investigated the treatment of melanoma, intestinal cancer,[5] and periodontitis.[6]

  1. ^ "4-Carbamothioylphenyl 2-(6-methoxynaphthalen-2-yl)propanoate". PubChem. National Institute of Health. Retrieved February 9, 2021.
  2. ^ "Otenaproxesul". IUPHAR/BPS Guide to Pharmacology. January 27, 2021.
  3. ^ "Otenaproxesul (ATB-346)". Antibe Therapeutics. 19 July 2019. Retrieved February 17, 2021.
  4. ^ "Otenaproxesul, (+/-)-". National Center for Advancing Translational Sciences. Retrieved February 9, 2021.
  5. ^ Elsheikh W, Blackler RW, Flannigan KL, Wallace JL (September 15, 2014). "Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer". Nitric Oxide. 41: 131–7. doi:10.1016/j.niox.2014.04.006. PMID 24747869 – via PubMed.
  6. ^ Gugliandolo E, Fusco R, D'Amico R, Militi A, Oteri G, Wallace JL, et al. (June 2018). "Anti-inflammatory effect of ATB-352, a H2S -releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats". Pharmacological Research. 132: 220–231. doi:10.1016/j.phrs.2017.12.022. PMID 29287688. S2CID 12099369.